Citations 14
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Ettinger, David S. , Wood, Douglas E. , Aisner, Dara L. , Akerley, Wallace , Bauman, Jessica R. , Bruno, Débora S. , Chirieac, Lucian R. , D’Amico, Thomas A., DeCamp, Malcolm M., Dilling, Thomas J. , Dowell, Jonathan E. , Gettinger, Scott , Gubens, Matthew A. , Lackner, Rudy P., Maldonado, Fabien , Morgensztern, Daniel , Ng, Thomas, Otterson, Gregory A. , Pacheco, Jose M., Patel, Sandip Pravin , Riely, Gregory J. , Riess, Jonathan W. , Shapiro, Theresa A. , Singh, Aditi P. , Stevenson, James, Tam, Alda L. , Yang, Stephen C. , Yau, Edwin , Gregory, Kristina M., Hughes, Miranda, Schild, Steven E. , Bharat, Ankit , Chang, Joe Y. , Grotz, Travis E. , Hegde, Aparna , Lanuti, Michael D. , Lin, Jules , Loo, Billy W. , Lovly, Christine Marie , Massarelli, Erminia , Tanvetyanon, Tawee , Yanagawa, Jane
Journal of the National Comprehensive Cancer Network | May 11, 2022 | Volume: 20 | Issue: 5 | Pages: 497-530
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non–Small Cell Lung Cancer (NSCLC) provide recommended management for patients with NSCLC, including diagnosis, primary treatment, surveillance for relapse, and subsequent treatment. Patients with metastatic lung cancer who are eligible for targeted therapies or immunotherapies are now surviving longer. This selection from the NCCN Guidelines for NSCLC focuses on targeted therapies for patients with metastatic NSCLC and actionable mutations.
Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Ganti, Apar Kishor , Bassetti, M. , Blakely, Collin M. , Chiang, Anne C. , D’Amico, Thomas A., D’Avella, Christopher , Dowlati, Afshin , Downey, Robert J. , Florsheim, Charles, Grecula, J.C., Hann, Christine L. , Iams, Wade T. , Iyengar, Puneeth , Khalil, Maya, Koczywas, Marianna , Merritt, Robert E. , Mohindra, Nisha , Molina, Julian R. , Moran, César A. , Qin, Angel , Rusthoven, Chad G. , Santana-Dávila, Rafael , Shafique, Michael , Gregory, Kristina M., Hughes, Miranda, Molina, Julian, Ganti, Apar K , Loo, Billy W. , Edelman, Martin J. , Gold, Kathryn Ann , Goldman, Jonathan W. , Kelly, Karen , Pokharel, Saraswati , Puri, Sonam , Sands, Jacob , Waqar, Saiama N
Journal of the National Comprehensive Cancer Network | December 13, 2021 | Volume: 19 | Issue: 12 | Pages: 1441-1464
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Small Cell Lung Cancer (SCLC) provide recommended management for patients with SCLC, including diagnosis, primary treatment, surveillance for relapse, and subsequent treatment. This selection for the journal focuses on metastatic (known as extensive-stage) SCLC, which is more common than limited-stage SCLC. Systemic therapy alone can palliate symptoms and prolong survival in most patients with extensive-stage disease. Smoking cessation counseling and intervention should be strongly promoted in patients with SCLC and other high-grade neuroendocrine carcinomas. The “Summary of the Guidelines Updates” section in the SCLC algorithm outlines the most recent revisions for the 2022 update, which are described in greater detail in this revised Discussion text.
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021
Ettinger, David S. , Wood, Douglas E. , Aisner, Dara L. , Akerley, Wallace , Bauman, Jessica R. , Bruno, Débora S. , Chirieac, Lucian R. , D’Amico, Thomas A., Dilling, Thomas J. , Dowell, Jonathan E. , Gettinger, Scott , Gubens, Matthew A. , Hegde, Aparna , Hennon, Mark, Lackner, Rudy P., Leal, Ticiana , Lin, Jules , Martins, Renato , Morgensztern, Daniel , Ng, Thomas, Otterson, Gregory A. , Patel, Sandip Pravin , Riely, Gregory J. , Shapiro, Theresa A. , Singh, Aditi P. , Stevenson, James, Tam, Alda L. , Yang, Stephen C. , Gregory, Kristina M., Hughes, Miranda, Schild, Steven E. , Bharat, Ankit , Chang, Joe Y. , Lanuti, Michael D. , Loo, Billy W. , Lovly, Christine Marie , Massarelli, Erminia , Yanagawa, Jane
Journal of the National Comprehensive Cancer Network | March 5, 2021 | Volume: 19 | Issue: 3 | Pages: 254-266
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non–Small Cell Lung Cancer (NSCLC) address all aspects of management for NSCLC. These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines regarding targeted therapies, immunotherapies, and their respective biomarkers.
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 1.2020
Ettinger, David S. , Wood, Douglas E. , Aisner, Dara L. , Akerley, Wallace , Bauman, Jessica R. , Bruno, Débora S. , Chirieac, Lucian R. , D’Amico, Thomas A., Dilling, Thomas J. , Dobelbower, M.C., Gettinger, Scott , Govindan, Ramaswamy , Gubens, Matthew A. , Hennon, Mark, Horn, Leora , Lackner, Rudy P., Leal, Ticiana , Lin, Jules , Loo, Billy W. , Martins, Renato , Otterson, Gregory A. , Patel, Sandip Pravin , Riely, Gregory J. , Shapiro, Theresa A. , Stevenson, James, Swanson, Scott J. , Tauer, Kurt W., Yang, Stephen C. , Gregory, Kristina M., OCN, Hughes, Miranda, Schild, Steven E. , Loo, Billy W , Govindan, Ramaswamy , Aggarwal, Charu , Bharat, Ankit , Chang, Joe Y. , Lanuti, Michael D. , Reckamp, Karen L. , OCN, Hughes, Miranda
Journal of the National Comprehensive Cancer Network | December 5, 2019 | Volume: 17 | Issue: 12 | Pages: 1464-1472
The NCCN Guidelines for Non–Small Cell Lung Cancer (NSCLC) address all aspects of management for NSCLC. These NCCN Guidelines Insights focus on recent updates in immunotherapy. For the 2020 update, all of the systemic therapy regimens have been categorized using a new preference stratification system; certain regimens are now recommended as “preferred interventions,” whereas others are categorized as either “other recommended interventions” or “useful under certain circumstances.”